COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01799486
Recruitment Status : Unknown
Verified February 2013 by Lin Bingliang, Sun Yat-sen University.
Recruitment status was:  Active, not recruiting
First Posted : February 26, 2013
Last Update Posted : February 26, 2013
Information provided by (Responsible Party):
Lin Bingliang, Sun Yat-sen University

Brief Summary:

Chronic hepatitis B virus (HBV) infection is a serious clinical problem because of its worldwide distribution and potential adverse outcome, including cirrhosis, which is a major cause of HBV related death. Studies show the use of nucleot(s)ide analogs treatment can alleviate, even reverse the progress of HBV-related cirrhosis. In cirrhosis stage, some potential factors, including endocrine disorder, renin, aldosterone, vasopressin increasing, hepatitis B virus related nephritis, hepatorenal syndrome, may cause renal damage. With the exposure of NAs, adverse reports of rhabdomyolysis, renal dysfunction, and lactic acidosis are increasing. So when choosing NAs, the potential renal function impairment should be considered.

Recently, Gane, Xiaoxi Li have separately reported that Telbivudine can improve estimate of glomerular filtration rate (eGFR) of patients with chronic hepatitis B, while eGFR of patients with Lamivudine, adefovir and entecavir have a trend of decrease, which suggested Telbivudine may have renal protective effects. This effect on patients with HBV-related liver cirrhosis has not been studied, which is not clear now.

This study is a randomized controlled study to prospectively observe Telbivudine's effect on renal function, which aims to provide evidence in antiviral treatment for the patients with cirrhosis.

Condition or disease Intervention/treatment Phase
HBV-related Liver Cirrhosis Drug: Telbivudine Drug: Enecavir Drug: Adefovir Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial
Study Start Date : February 2013
Actual Primary Completion Date : February 2013
Estimated Study Completion Date : March 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cirrhosis
Drug Information available for: Telbivudine

Arm Intervention/treatment
Experimental: Telbivudine
Telbivudine,600mg/d,oral,100patients,2 years.
Drug: Telbivudine
600 mg monotherapy supplied in film-coated tablets.
Other Name: No.

Experimental: Adefovir
Adefovir,10mg/d,oral,100 patients,2years.
Drug: Enecavir
0.5 mg monotherapy supplied in tablets.
Other Name: No.

Experimental: Enecavir
Enecavir,0.5mg/d,oral,100 patients,2 year
Drug: Adefovir
10 mg monotherapy supplied in tablets.
Other Name: No.

Primary Outcome Measures :
  1. Change of estimate of glomerular filtration rate (eGFR)* and Serum creatinine in week 4,12,18,24,48,72,96 in each Group. [ Time Frame: up to 2years ]

Secondary Outcome Measures :
  1. Liver function change (ALB/GLB, ALT/AST, TB) in each Group [ Time Frame: up to 2 years ]

Other Outcome Measures:
  1. Percentage of subjects with ALT normalization rate at year 1and year 2 in each Group. [ Time Frame: up to 2 years ]
  2. The rate of complications (ascites, hepatorenal syndrome and so on) [ Time Frame: up to 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:Subjects eligible for enrolment in the study must meet all of the following criteria:

  • eGFR in baseline less than 90 ml.min-1.1.73m2
  • Aged between 18-75 years (inclusive).
  • Male or female.
  • Subjects with positive HBsAg for more than 6 months and anti-HBs negative regardless of HBeAg status. If eAg+, HBV DNA ≥2×104 IU/ml and <2×108 IU/ml; If eAg-, HBV DNA ≥2×103 IU/ml and <2×106 IU/ml.
  • Subjects with HBV-related liver cirrhosis, including compensated cirrhosis and decompensated, but only Child-Pugh A or B. Cirrhosis was diagnosed by the evidence of a small, nodular liver, as shown by ultrasound, computerized omography (CT), and magnetic resonance (MR), with the exclusion of primary biliary cirrhosis and cirrhosis caused by schistosome.
  • The ablility to understand and sign a written informed consent prior to any study related procedure and comply with the requirements of the study.

Exclusion Criteria:

Subjects meeting any of the following criteria must not be enrolled in the study

  • History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures
  • Patient is pregnant or breastfeeding.
  • Subjects with non-HBV cirrhosis
  • Co-infection with HAV/HCV/HDV/ HIV
  • Patients who have previously been involved in a trial with telbivudine.
  • Patient has received nucleoside or nucleotide drugs whether approved or investigational at any time.
  • Patient has received IFN or other immunomodulatory treatment in the 6 months before Screening for this study.
  • Patient has a history of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin. Patients with previous findings suggestive of possible hepatocellular carcinoma (HCC), should have the disease ruled out prior to entrance into the study.
  • Patient has one or more additional known primary or secondary causes of liver disease other than CHB, including steatohepatitis,autoimmune hepatitis and so on. Gilbert's syndrome and Dubin-Johnson syndrome are not considered exclusion criteria for this study.
  • History of any other acute or chronic medical condition that in the opinion of the investigator would make the patient unsuitable for inclusion into the study.
  • Patient is currently abusing alcohol or illicit drugs, or has a history of alcohol abuse or illicit substance abuse within the preceding two years.
  • Patient has a medical condition that requires frequent or prolonged use of systemic corticosteroids, although inhaled corticosteroids are allowed.
  • Patient has a history of clinical and laboratory evidence of chronic renal insufficiency.
  • Patient has a medical condition requiring the chronic or prolonged use of potentially hepatotoxic drugs or nephrotoxic drugs.
  • Patient has any other concurrent medical or social condition likely to preclude compliance with the schedule of evaluations in the protocol, or likely to confound the efficacy or safety observations of the study.
  • Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.
  • Patient has a history of myopathy, myositis, or persistent muscle weakness.
  • Kidney impairment due to non-HBV factors
  • Inability to comply with study requirements as determined by the study investigator
  • Patients with eGFR≤15 ml.min-1.1.73m2, who may need dialysis or renal transplantation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01799486

Sponsors and Collaborators
Lin Bingliang
Layout table for investigator information
Study Chair: Lin Bingliang, PhD Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University
Layout table for additonal information
Responsible Party: Lin Bingliang, The Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University Identifier: NCT01799486    
Other Study ID Numbers: Professor Bingliang Lin
First Posted: February 26, 2013    Key Record Dates
Last Update Posted: February 26, 2013
Last Verified: February 2013
Keywords provided by Lin Bingliang, Sun Yat-sen University:
renoprotective efficacy
liver cirrhosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Cirrhosis
Pathologic Processes
Liver Diseases
Digestive System Diseases
Antiviral Agents
Anti-Infective Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents